JP2014510156A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510156A5 JP2014510156A5 JP2014504039A JP2014504039A JP2014510156A5 JP 2014510156 A5 JP2014510156 A5 JP 2014510156A5 JP 2014504039 A JP2014504039 A JP 2014504039A JP 2014504039 A JP2014504039 A JP 2014504039A JP 2014510156 A5 JP2014510156 A5 JP 2014510156A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- topical
- semi
- prostaglandin
- dimethylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 12
- 230000000699 topical effect Effects 0.000 claims 12
- 239000008247 solid mixture Substances 0.000 claims 11
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 8
- 150000001733 carboxylic acid esters Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 150000004676 glycans Chemical class 0.000 claims 6
- 229920001282 polysaccharide Polymers 0.000 claims 6
- 239000005017 polysaccharide Substances 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 208000003782 Raynaud disease Diseases 0.000 claims 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 4
- -1 prostaglandin E 1 compound Chemical class 0.000 claims 4
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims 4
- 239000002562 thickening agent Substances 0.000 claims 3
- KIPQYJOLEGBNHQ-UHFFFAOYSA-N 1-(dimethylamino)propan-2-yl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)CN(C)C KIPQYJOLEGBNHQ-UHFFFAOYSA-N 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- HSMMSDWNEJLVRY-INIZCTEOSA-N dodecyl (2s)-2-(dimethylamino)propanoate Chemical group CCCCCCCCCCCCOC(=O)[C@H](C)N(C)C HSMMSDWNEJLVRY-INIZCTEOSA-N 0.000 claims 2
- IHSPMDXQWYKHOA-UHFFFAOYSA-N dodecyl 2-(dimethylamino)acetate Chemical compound CCCCCCCCCCCCOC(=O)CN(C)C IHSPMDXQWYKHOA-UHFFFAOYSA-N 0.000 claims 2
- 229940049964 oleate Drugs 0.000 claims 2
- 239000003961 penetration enhancing agent Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 2
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- PUIBPGHAXSCVRF-QHFGJBOXSA-N prostaglandin C1 Chemical compound CCCCC[C@H](O)\C=C\C1=CCC(=O)[C@@H]1CCCCCCC(O)=O PUIBPGHAXSCVRF-QHFGJBOXSA-N 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161472988P | 2011-04-07 | 2011-04-07 | |
| US61/472,988 | 2011-04-07 | ||
| PCT/US2012/032577 WO2012139033A1 (en) | 2011-04-07 | 2012-04-06 | Methods and compositions for treating raynaud's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014510156A JP2014510156A (ja) | 2014-04-24 |
| JP2014510156A5 true JP2014510156A5 (https=) | 2015-04-23 |
Family
ID=46969575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504039A Pending JP2014510156A (ja) | 2011-04-07 | 2012-04-06 | レイノー病を治療する方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US8940794B2 (https=) |
| EP (1) | EP2693877A4 (https=) |
| JP (1) | JP2014510156A (https=) |
| BR (1) | BR112013025744A2 (https=) |
| CA (1) | CA2838109C (https=) |
| MX (1) | MX342511B (https=) |
| RU (1) | RU2633236C2 (https=) |
| WO (1) | WO2012139033A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004227853A1 (en) | 2003-04-02 | 2004-10-21 | Nexmed (Holdings), Inc. | Prostaglandin compositions and their use for the treatment of vasospasm |
| WO2012139033A1 (en) | 2011-04-07 | 2012-10-11 | Nexmed Holdings, Inc. | Methods and compositions for treating raynaud's disease |
| MX2015010041A (es) * | 2013-02-05 | 2015-10-30 | Purdue Pharma Lp | Formulacion farmaceuticas resistentes a la alteracion. |
| CN109288848A (zh) * | 2018-11-27 | 2019-02-01 | 西安力邦肇新生物科技有限公司 | 前列腺素e1甲酯在制备扩张血管药物中的应用 |
| US20240299413A1 (en) | 2020-08-07 | 2024-09-12 | Eicos Sciences, Inc. | Method of treating systemic sclerosis with symptomatic raynaud's phenomenon by intravenous or subcutaneous iloprost administration |
| WO2025019625A1 (en) | 2023-07-18 | 2025-01-23 | Btg International Inc. | Method of using iloprost for treating frostbite |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4029814A (en) | 1975-12-29 | 1977-06-14 | The Upjohn Company | Phenyl-substituted prostaglandin-e type analogs |
| US4212987A (en) | 1976-09-17 | 1980-07-15 | The Upjohn Company | 2,2-Difluoro-PGE1 analogs |
| US4311707A (en) | 1979-02-12 | 1982-01-19 | American Cyanamid Company | Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions |
| US4820732A (en) | 1985-10-04 | 1989-04-11 | The Upjohn Company | Method and compositions for reducing dysfunction in angioplasty procedures |
| US4955878A (en) | 1986-04-04 | 1990-09-11 | Biotechnology, Inc. | Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures |
| US5219885A (en) * | 1987-02-16 | 1993-06-15 | Froelich Juergen | Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration |
| DE3704825A1 (de) * | 1987-02-16 | 1988-08-25 | Froelich Juergen | Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung |
| US5082866A (en) | 1988-06-01 | 1992-01-21 | Odontex, Inc. | Biodegradable absorption enhancers |
| US4980378A (en) | 1988-06-01 | 1990-12-25 | Odontex, Inc. | Biodegradable absorption enhancers |
| ES2093774T3 (es) | 1991-03-14 | 1997-01-01 | R Tech Ueno Ltd | Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina. |
| US5403867A (en) | 1992-02-07 | 1995-04-04 | Kaken Pharmaceutical Co., Ltd. | Preparation for treating wounds or hemorrhoids |
| ATE285212T1 (de) | 1993-10-07 | 2005-01-15 | Odontex Inc | Absorptionsförderer für topische pharmazeutische formulierungen |
| US5380760A (en) | 1993-11-19 | 1995-01-10 | Minnesota Mining And Manufacturing Company | Transdermal prostaglandin composition |
| US20020165122A1 (en) | 1994-04-22 | 2002-11-07 | Heaton Jeremy P. W. | Method and compositions for the treatment or amelioration of female sexual dysfunction |
| US5952006A (en) | 1995-09-29 | 1999-09-14 | L.A.M. Pharmaceuticals, Llc | Drug preparations for treating impotency |
| US6046244A (en) | 1997-11-05 | 2000-04-04 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin E1 delivery |
| US6414028B1 (en) | 1997-11-05 | 2002-07-02 | Nexmed Holdings, Inc. | Topical compositions containing prostaglandin E1 |
| TW473834B (en) | 1998-05-01 | 2002-01-21 | Ibm | Method of doping a gate and creating a very shallow source/drain extension and resulting semiconductor |
| US5942545A (en) | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
| US7087240B1 (en) | 1998-06-25 | 2006-08-08 | Lavipharm Laboratories Inc. | Device and method for the treatment of erectile dysfunction |
| US6007824A (en) | 1998-07-09 | 1999-12-28 | Duckett; Melvin J. | Natural composition and method for the treatment of sexual dysfunction |
| US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| CA2442479C (en) | 1999-05-13 | 2005-12-13 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin e1 delivery |
| US6118020A (en) | 1999-05-19 | 2000-09-12 | Nexmed Holdings, Inc. | Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate |
| US6323241B1 (en) | 2000-01-10 | 2001-11-27 | Nexmed (Holdings) Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| US7105571B2 (en) | 2000-01-10 | 2006-09-12 | Nexmed Holdings, Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| US7105572B2 (en) | 2000-02-04 | 2006-09-12 | Takeda Pharmaceutical Company Limited | Stable emulsion compositions |
| US20060148907A1 (en) | 2002-07-24 | 2006-07-06 | Nicholson David M | Topical antinflammatory preparations of y-terpinene |
| EP1558614B1 (en) | 2002-10-30 | 2010-09-01 | Merck Frosst Canada Ltd. | Pyridopyrrolizine and pyridoindolizine derivatives |
| US20050181030A1 (en) | 2003-01-03 | 2005-08-18 | Mo Y. J. | Topical stabilized prostaglandin E compound dosage forms |
| US6841574B2 (en) | 2003-01-03 | 2005-01-11 | Nexmed Holdings, Inc. | Topical stabilized prostaglandin E compound dosage forms |
| AU2004227853A1 (en) | 2003-04-02 | 2004-10-21 | Nexmed (Holdings), Inc. | Prostaglandin compositions and their use for the treatment of vasospasm |
| PL2084124T3 (pl) * | 2006-10-02 | 2014-08-29 | Techfields Biochem Co Ltd | Dodatnio naładowane rozpuszczalne w wodzie proleki prostaglandyn i związków pokrewnych o bardzo dużych szybkościach przenikania przez skórę |
| EP2011496A1 (en) | 2007-07-03 | 2009-01-07 | Indena S.P.A. | Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions |
| AR068409A1 (es) * | 2007-09-14 | 2009-11-18 | Drugtech Corp | Composiciones farmaceuticas, transdermicas sin alcohol |
| WO2012139033A1 (en) | 2011-04-07 | 2012-10-11 | Nexmed Holdings, Inc. | Methods and compositions for treating raynaud's disease |
-
2012
- 2012-04-06 WO PCT/US2012/032577 patent/WO2012139033A1/en not_active Ceased
- 2012-04-06 JP JP2014504039A patent/JP2014510156A/ja active Pending
- 2012-04-06 EP EP12767469.5A patent/EP2693877A4/en active Pending
- 2012-04-06 RU RU2013141836A patent/RU2633236C2/ru active
- 2012-04-06 BR BR112013025744A patent/BR112013025744A2/pt not_active Application Discontinuation
- 2012-04-06 US US14/110,348 patent/US8940794B2/en active Active
- 2012-04-06 CA CA2838109A patent/CA2838109C/en active Active
- 2012-04-06 MX MX2013011662A patent/MX342511B/es active IP Right Grant
-
2015
- 2015-01-07 US US14/591,487 patent/US9517218B2/en active Active
-
2016
- 2016-07-29 US US15/224,098 patent/US9855231B2/en not_active Expired - Fee Related
-
2017
- 2017-12-15 US US15/844,361 patent/US10632086B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| JP2014510156A5 (https=) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| WO2012054831A3 (en) | Ready to use ketorolac formulations | |
| JP2009102342A5 (https=) | ||
| JP2013542247A5 (https=) | ||
| WO2012079092A3 (en) | Testosterone undecanoate compositions | |
| SG10201407013QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
| JP2014515373A5 (https=) | ||
| JP2016512248A5 (https=) | ||
| JP2014521735A5 (https=) | ||
| JP2012529484A5 (ja) | 高血圧症の防止及び治療のための組成物並びに方法 | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| NZ703808A (en) | Topical transdermal dexmedetomidine compositions and methods of use thereof | |
| JP2010510286A5 (https=) | ||
| JP2013516493A5 (https=) | ||
| JP2012193216A5 (https=) | ||
| NZ592217A (en) | Methods of treating pulmonary disorders with liposomal amikacin formulations | |
| JP2015505295A5 (https=) | ||
| JP2012517449A5 (https=) | ||
| ITBO20110012A1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2013541583A5 (https=) | ||
| CA2692191C (en) | Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases | |
| JP2013534228A5 (https=) |